Cord Blood News Volume 4.34 | Aug 30 2012

Correlation of Clinical Response and Response Duration with miR-145 Induction by Lenalidomide in CD34+ Cells from Patients with del(5q) Myelodysplastic Syndrome
Researchers examined whether lenalidomide exposure upregulates miRNAs and mRNAs, previously shown to play a role in the disease phenotype of del(5q) myelodysplastic syndrome, in pretreatment CD34+ marrow cells. Knockdown of miR-143 and miR-145 in cord blood CD34+ cells resulted in increased erythroid progenitor activity. [Haematologica] Abstract | Full Article

Human Responses against HER-2-Positive Cancer Cells in Human Immune System-Engrafted Mice
Researchers used human immune system (HIS)-engrafted mice to study human immune responses against human HER-2-positive cancer cells and their ability to control tumor growth and metastasis. BALB/c Rag2^−/−, Il2rg^−/− mice were engrafted with CD34⁺ or CD133⁺ human cord blood hematopoietic stem cells and vaccinated with human HER-2-positive cancer cells SK-OV-3 combined to human IL-12. [Br J Cancer]
Full Article

Human Intestinal Dendritic Cells Decrease Cytokine Release against Salmonella Infection in the Presence of Lactobacillus paracasei upon Toll-Like Receptor Activation
Scientists used human dendritic cells (DCs) generated from CD34+ progenitor cells harvested from umbilical cord blood. They reported that both a novel probiotic strain isolated from feces of exclusively breast-fed newborn infants, Lactobacillus paracasei CNCM I-4034, and its cell-free culture supernatant decreased pro-inflammatory cytokines and chemokines in human intestinal DCs challenged with Salmonella. [PLoS One]
Full Article

Intravenous Grafts Of Amniotic Fluid-Derived Stem Cells Induce Endogenous Cell Proliferation and Attenuate Behavioral Deficits in Ischemic Stroke Rats
Researchers tested the therapeutic benefits of amniotic fluid-derived stem cells in a rodent model of ischemic stroke. [PLoS One] Full Article

The Alleviation of Acute and Chronic Kidney Injury by Human Wharton’s Jelly-Derived Mesenchymal Stromal Cells Triggered by Ischemia-Reperfusion Injury via an Endocrine Mechanism
Scientists found that Wharton’s jelly-derived mesenchymal stromal cells (WJ-MSC) alleviate acute kidney injury, thereby rescuing the ensuing fibrotic lesions in an endocrine manner. The Akt signal in impaired tubular cells is reinforced by WJ-MSC, facilitating cell resistance to apoptosis and cell proliferation. Hepatocyte growth factor, either delivered or induced by WJ-MSC, is an important contributor. [Cytotherapy] Abstract

Human Wharton’s Jelly Stem Cell Conditioned Medium and Cell-Free Lysate Inhibit Human Osteosarcoma and Mammary Carcinoma Cell Growth In Vitro and in Xenograft Mice
Researchers examined the influence of human Wharton’s jelly stem cell conditioned medium and cell-free lysate on two osteosarcoma cell lines in vitro and on human mammary carcinomas in immunodeficient mice. [J Cell Biochem] Abstract

Humanized Mice Have Functional Human Neutrophils
Researchers generated humanized mice by injecting human cord blood derived CD34 + stem cells into irradiated NOD-scid-γc^−/− mice. At least three months after engraftment, treatment of mice with GCSF mobilized circulating human neutrophils, which comprised 2.6% of human leukocytes, and led to L-selectin shedding and upregulation of CD66b, CD11b and CD63. [J Immunol Methods] Abstract

Simultaneous Detection of the Two Main Proliferation Driving EBV Encoded Proteins, EBNA-2 and LMP-1 in Single B Cells
Investigators show for the first time the occurrence of Type IIa and Type IIb cells in cord blood lymphocyte populations infected with Epstein Barr virus in vitro. [J Immunol Methods] Abstract

America Stem Cell, Inc. Initiates a Phase I/II Trial of ASC-101 in Patients with Hematologic Malignancies Undergoing Dual-Cord Transplantation
America Stem Cell, Inc. announced the initiation of a single-center study at The University of Texas MD Anderson Cancer Center evaluating ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies. [Business Wire] Press Release

ThermoGenesis Announces Completion of CryoSeal® Product Line Transaction with Asahi
ThermoGenesis Corp. announced that it has received the $2 million cash payment from Asahi Kasei Medical Co., Ltd., associated with the sale of the CryoSeal Fibrin Sealant System to Asahi. [ThermoGenesis Corp.] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Stem Cell Therapy Scientist (Paramount Recruitment)

Clinical Lab Scientist – Cord Blood (Cardinal Glennon Children’s Medical Center)

Postdoctoral Position – Molecular Biology (Faculty of Informatics, Masaryk University)

Postdoctoral Position – Stem Cell Research (Connecticut Children’s Medical Center, University of Connecticut)

Postdoctoral Fellow – Stem Cell Biology and Developmental Hematopoiesis (Mount Sinai School of Medicine)

Research Associate – Quality Assurance (University of California)


Recruit Top Talent: Reach more than 55,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.